MRUGESH C PANCHANI

Allopathic & Osteopathic Physicians|Internal Medicine|Nephrology BRICK, NJ NPI 1013213206

General Payments — all program years on this page

$2,679.49

  • Category: General Payments
  • Program years: PY2018–2024
  • Record count: 108
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $1,019.00 across 18 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Food and Beverage $1,019.0018

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
Acerta Pharma LLC $556.9310
LeMaitre Vascular, Inc. $256.542
Ardelyx, Inc. $154.863
Amgen Inc. $33.322
Boehringer Ingelheim Pharmaceuticals, Inc. $17.351

By program year

Program yearAmountRecords
2018 $316.2323
2019 $464.1433
2020 $129.289
2021 $28.252
2022 $95.727
2023 $626.8716
2024 $1,019.0018

Records — PY2024 (18)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1104365351 AstraZeneca Pharmaceuticals LP $1.55 10/10/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104683415 AstraZeneca Pharmaceuticals LP $125.00 03/14/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104711029 AstraZeneca Pharmaceuticals LP $118.99 02/13/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104747061 AstraZeneca Pharmaceuticals LP $19.21 08/29/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105240642 AstraZeneca Pharmaceuticals LP $16.81 04/09/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105348611 AstraZeneca Pharmaceuticals LP $15.82 10/11/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105537140 AstraZeneca Pharmaceuticals LP $19.79 09/17/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105811133 AstraZeneca Pharmaceuticals LP $113.43 04/24/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105839713 AstraZeneca Pharmaceuticals LP $110.72 01/24/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105862832 AstraZeneca Pharmaceuticals LP $15.61 12/10/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1115990549 Amgen Inc. $14.37 07/12/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1117648265 Amgen Inc. $18.95 12/20/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1117835972 Boehringer Ingelheim Pharmaceuticals, Inc. $17.35 09/05/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1138049371 LeMaitre Vascular, Inc. $128.27 03/05/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1138049375 LeMaitre Vascular, Inc. $128.27 03/05/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1146699225 Ardelyx, Inc. $124.72 01/18/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1146699227 Ardelyx, Inc. $16.64 08/30/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1146699229 Ardelyx, Inc. $13.50 09/12/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.